시장보고서
상품코드
1826863

세계의 아메바성 이질 시장 보고서(2025년)

Amebiasis Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

아메바성 이질 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 8억 2,000만 달러에서 2025년에는 8억 8,000만 달러에 달하고, CAGR 6.6%를 나타낼 전망입니다. 실적기간의 성장은 열대지역에서의 아메바 감염증의 발생률 증가, 개발도상국의 위생습관의 부족, 특히 유행지역으로의 해외도항 증가, 질병에 대한 의식의 높아짐, 농촌에서의 청결한 식수에 대한 접근부족 등에 기인한다고 생각됩니다.

아메바성 이질 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 6.5%를 나타내 11억 3,000만 달러로 성장할 전망입니다. 예측기간 성장의 배경으로는 면역결핍 인구 증가, 위생환경 및 헬스케어 인프라 개선을 위한 정부 이니셔티브 증가, 새로운 치료법에 대한 조사 투자 증가, 기생충 질환과 싸우기 위한 건강 이니셔티브에 대한 주목이 높아지고, 효과적인 경구약에 대한 수요 증가 등이 있습니다. 예측기간의 주요 동향으로는 병용요법의 채용확대, 백신의 개발, 약물전달 시스템의 진보, 제약 연구의 진보, 신규 항기생충약의 개발 등을 들 수 있습니다.

아메바성 이질은 기생충 * Entamoeba histolytica *에 의해 야기되는 장내 감염이며, 종종 설사, 복통, 경우에 따라 간 농양과 같은 증상을 유발합니다. 이 감염은 메트로니다졸과 티니다졸과 같은 약물로 치료되지만, 이러한 약물은 장과 조직 모두에서 기생충을 대상으로 작용합니다.

아메바성 이질의 치료에 사용되는 주요 약물은 메트로니다졸, 파로모마이신, 티니다졸이 있습니다. 메트로니다졸은 항생제이며 특정 세균과 기생충의 DNA를 파괴하여 제거하므로 아메바성 이질 치료에 효과적입니다. 메트로니다졸은 경구 투여 및 정맥 내 투여 등 다양한 경로로 투여되며, 병원이나 약국 등의 건강 관리 현장에서 일반적으로 사용되고 있습니다.

2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.

이 조사 보고서는 아메바성 이질 업계 세계 시장 규모, 지역 점유율, 아메바성 이질 시장 점유율을 가진 경쟁업체, 상세한 아메바성 이질 시장 부문, 시장 동향, 비즈니스 기회 등 아메바성 이질 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 아메바성 이질 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.

향후 5년간의 성장률 6.5%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역마찰은 인도나 벨기에에서 개발된 니트로이미다졸계 항생제와 진단용 중합효소 연쇄반응(PCR) 키트의 가격을 상승시켜 기생충 식별 지연 및 열대병 치료비 상승을 초래하는 등 미국의 감염증 치료에 지장을 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

기생충 감염의 이환율 증가는 아메바성 이질 시장 성장을 가속할 것으로 예측됩니다. 기생충 감염은 원충, 기생충, 외부 기생충과 같은 생물에 의해 유발되며 숙주 또는 숙주 내부에 서식하고 숙주의 희생에 영양을 얻습니다. 여행자 증가, 기후 변화, 열악한 위생환경, 약물내성 증가 등 다양한 요인들이 이러한 감염의 만연과 지속에 기여하고 있습니다. 장관 출혈성 대장균(Entamoeba histolytica)에 의해 야기되는 아메바성 이질은 장에 침입하여 설사나 복통 등의 증상을 일으켜 조직 손상이나 간농양 등 심각한 합병증을 일으켜 기생충 감염에 중요한 역할을 하고 있습니다. 예를 들어 영국 정부 기관인 동식물 위생청(Animal and Plant Health Agency)은 2024년 1월, 2022년 기생충성 위장염(PGE) 환자 수 1,071례(그중 헤모키나제증 190례, 선충증 95례)를 보고했습니다. 헤몬쿠시스 증례 수는 전년을 현저하게 웃돌았습니다. 그 결과, 기생충 감염의 유병률 증가가 아메바성 이질 시장 확대에 박차를 가하고 있습니다.

열악한 위생환경이 만연하고 있는 것도 아메바성 이질 시장 성장에 기여하고 있습니다. 깨끗한 물에 대한 부적절한 접근, 부적절한 폐수 처리, 비위생 시설을 포함한 열악한 위생 환경은 감염의 확산을 촉진합니다. 특히 개발도상지역에서는 적절한 폐기물 관리 부족, 불충분한 인프라, 급속한 도시화, 청결한 물 접근 제한 등이 위생불량의 만연을 촉진하는 주요 요인이 되고 있습니다. 오염된 물과 식품원은 기생충인 엔타모에바 히스트리티카의 만연을 조장하는 환경을 만들어내기 때문에 아메바성 이질은 이러한 상황하에서 증식합니다. 예를 들어, 2023년 7월 유엔수기관은 2022년 20억 명이 기본 위생 서비스를 이용할 수 없었으며 35억 명이 안전하게 관리된 위생 시설을 이용할 수 없었다고 보고했습니다. 이 광범위한 문제는 아메바 증 시장에서 솔루션 수요를 계속 견인하고 있습니다.

아메바성 이질 시장 주요 기업들은 환자의 컴플라이언스와 치료 효과를 높이기 위해 즉시 사용할 수 있는 경구 액체 메트로니다졸과 같은 혁신적인 진보에 주목하고 있습니다. 이 준비된 액체 항생제 제제는 특히 정제의 삼키기가 어려운 환자의 치료를 단순화하도록 설계되었습니다. 2023년 11월, 미국 제약회사 케신 퍼머 코퍼레이션은 미국 식품의약국에서 리쿠메스(메트로니다졸) 경구 현탁액 500mg/5mL의 승인을 취득했습니다. 이것은 메트로니다졸의 경구 액체 제형으로는 처음입니다. 이 경구 현탁액은 소아에게 적합한 대체품이며, 소아에서도 정확한 복용이 용이해지므로 치료 프로토콜의 어드히어런스가 향상됩니다. 게다가, 액체 제형은 복용량에 융통성이 있기 때문에 건강 관리 담당자는 감염의 중증도 및 개별 환자의 필요에 따라 치료를 조정할 수 있습니다.

아메바성 이질 시장에는 의료 상담 및 치료 관리, 예방 접종 및 예방 서비스, 의약품 서비스, 진단 검사 서비스 등의 서비스를 제공하는 기업이 얻는 수익이 포함됩니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치도 포함됩니다. 아메바성 이질 시장에는 항기생충제, 진단 키트, 백신, 프로바이오틱스 판매도 포함됩니다. 이 시장의 가치는 '팩토리 게이트(공장 출하 시)' 가치이며, 즉 다른 기업(다운스트림 제조업자, 도매업체, 유통업체, 소매업체 포함)이든 직접 최종 고객이든, 상품 제조업체 또는 제조업체가 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계의 아메바성 이질 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
  • 최종 이용 산업의 분석
  • 세계의 아메바성 이질 시장 : 성장률 분석
  • 세계의 아메바성 이질 시장 실적 : 규모와 성장(2019-2024년)
  • 세계의 아메바성 이질 시장 예측 : 규모와 성장(2024-2029년, 2034년)
  • 세계의 아메바성 이질 : 전체 시장 규모(TAM)

제6장 시장 세분화

  • 세계의 아메바성 이질 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 메트로니다졸
  • 파로모마이신
  • 티니다졸
  • 세계의 아메바성 이질 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 경구
  • 정맥 내
  • 세계의 아메바성 이질 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 병원
  • 약국
  • 세계의 아메바성 이질 시장 : 메트로니다졸 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 경구용 메트로니다졸
  • 정맥주사용 메트로니다졸
  • 메트로니다졸 병용 요법
  • 세계의 아메바성 이질 시장 : 파로모마이신 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 경구용 파로모마이신
  • 다른 약제와 병용하는 파로모마이신
  • 세계의 아메바성 이질 시장 : 티니다졸 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 경구용 티니다졸
  • 중증 감염용 티니다졸

제7장 지역별/국가별 분석

  • 세계의 아메바성 이질 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 세계의 아메바성 이질 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 아메바성 이질 시장 : 경쟁 구도
  • 아메바성 이질 시장 : 기업 프로파일
    • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
    • AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH
  • Siemens Healthineers AG
  • Becton Dickinson and Company
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Cepheid Inc.
  • Mission Pharmacal Company
  • Profounda Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

  • 아메바성 이질 시장(2029년) : 새로운 기회를 제공하는 국가
  • 아메바성 이질 시장(2029년) : 새로운 기회를 제공하는 부문
  • 아메바성 이질 시장(2029년) : 성장 전략
    • 시장 동향에 기초한 전략
    • 경쟁 전략

제36장 부록

KTH 25.10.17

Amebiasis is an intestinal infection caused by the parasite *Entamoeba histolytica*, often resulting in symptoms such as diarrhea, abdominal pain, and, in some cases, liver abscesses. This infection is treated with medications such as metronidazole and tinidazole, which work by targeting the parasite in both the gut and tissues.

The primary drugs used to treat amebiasis include metronidazole, paromomycin, and tinidazole. Metronidazole is an antibiotic that eliminates certain bacteria and parasites by disrupting their DNA, making it an effective treatment for amebiasis. The medications can be administered through various routes, including oral and intravenous, and are commonly used in healthcare settings such as hospitals and pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The amebiasis market research report is one of a series of new reports from The Business Research Company that provides amebiasis market statistics, including the amebiasis industry global market size, regional shares, competitors with the amebiasis market share, detailed amebiasis market segments, market trends, and opportunities, and any further data you may need to thrive in the amebiasis industry. This amebiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The amebiasis market size has grown strongly in recent years. It will grow from $0.82 billion in 2024 to $0.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increasing incidence of amoebic infections in tropical regions, poor sanitation and hygiene practices in developing countries, increasing international travel, especially to endemic areas, growing awareness about the disease, and lack of access to clean drinking water in rural areas.

The amebiasis market size is expected to see strong growth in the next few years. It will grow to $1.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising prevalence of immune-compromised populations, increasing government initiatives to improve sanitation and healthcare infrastructure, growing investments in research for new treatments, increasing focus on health initiatives to combat parasitic diseases, and growing demand for effective oral medications. Major trends in the forecast period include growing adoption of combination therapies, development of vaccines, advancements in drug delivery systems, advancements in pharmaceutical research, and development of novel antiprotozoal drugs.

The forecast of 6.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. infectious disease treatment by inflating prices of nitroimidazole antibiotics and diagnostic Polymerase Chain Reaction(PCR) kits developed in India and Belgium, resulting in delayed parasite identification and higher tropical medicine costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of parasitic infections is expected to drive the growth of the amebiasis market. Parasitic infections are caused by organisms such as protozoa, helminths, or ectoparasites that live on or inside a host, deriving nutrients at the host's expense. Various factors, including increased travel, climate change, poor sanitation, and growing drug resistance, contribute to the spread and persistence of these infections. Amebiasis, caused by the Entamoeba histolytica parasite, plays a significant role in parasitic infections by invading the intestines and leading to symptoms such as diarrhea, abdominal pain, and severe complications such as tissue damage and liver abscesses. For example, in January 2024, the Animal and Plant Health Agency, a UK-based government agency, reported 1,071 cases of Parasitic Gastroenteritis (PGE) in 2022, including 190 cases of haemonchosis and 95 cases of nematodirosis. The number of haemonchosis cases was notably higher than in the previous year. As a result, the increasing prevalence of parasitic infections is fueling the expansion of the amebiasis market.

The widespread issue of poor sanitation is also contributing to the growth of the amebiasis market. Poor sanitation, which includes inadequate access to clean water, improper sewage disposal, and unhygienic facilities, facilitates the spread of infectious diseases. The lack of proper waste management, insufficient infrastructure, rapid urbanization, and limited access to clean water, especially in developing regions, are key factors driving the prevalence of poor sanitation. Amebiasis thrives in such conditions, as contaminated water and food sources create an environment conducive to the spread of the Entamoeba histolytica parasite. For instance, in July 2023, the United Nations Water agency reported that in 2022, 2 billion people lacked access to basic hygiene services, while 3.5 billion did not have safely managed sanitation. This widespread issue continues to drive the demand for solutions in the amebiasis market.

Leading companies in the amebiasis market are focusing on innovative advancements such as ready-to-use oral liquid metronidazole to enhance patient compliance and treatment effectiveness. This pre-prepared liquid antibiotic formulation is designed to simplify treatment, particularly for individuals who have difficulty swallowing pills. In November 2023, Kesin Pharma Corporation, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for Likmez (metronidazole) oral suspension, 500 mg/5 mL. This marks the first ready-to-use oral liquid formulation of metronidazole. The oral suspension provides a pediatric-friendly alternative, making it easier for children to take the medication with accurate dosing, thereby improving adherence to treatment protocols. Additionally, the liquid formulation offers dosing flexibility, allowing healthcare providers to tailor treatment based on the severity of infections and individual patient needs.

Major players in the amebiasis market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Cepheid Inc., Mission Pharmacal Company, Profounda Inc., and Zydus Lifesciences Limited.

North America was the largest region in the amebiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in amebiasis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the amebiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The amebiasis market includes revenues earned by entities by providing services such as medical consultation and treatment management, vaccination and preventive services, pharmaceutical services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The amebiasis market also includes sales of antiprotozoal medications, diagnostic kits, vaccines, and probiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Amebiasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on amebiasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for amebiasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The amebiasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Metronidazole; Paromomycin; Tinidazole
  • 2) By Route Of Administration: Oral; Intravenous
  • 3) By Application: Hospital; Pharmacy
  • Subsegments:
  • 1) By Metronidazole: Oral Metronidazole; Intravenous Metronidazole; Combination Therapy with Metronidazole
  • 2) By Paromomycin: Oral Paromomycin; Paromomycin in Combination with Other Drugs
  • 3) By Tinidazole: Oral Tinidazole; Tinidazole for Severe Infections
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Sanofi SA; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; Novartis AG; F. Hoffmann-La Roche Ltd; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Boehringer Ingelheim International GmbH; Siemens Healthineers AG; Becton Dickinson and Company; Teva Pharmaceutical Industries Ltd.; Cipla Limited; Hikma Pharmaceuticals PLC; Lupin Limited; Cepheid Inc.; Mission Pharmacal Company; Profounda Inc.; Zydus Lifesciences Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Amebiasis Market Characteristics

3. Amebiasis Market Trends And Strategies

4. Amebiasis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Amebiasis Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Amebiasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Amebiasis Market Growth Rate Analysis
  • 5.4. Global Amebiasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Amebiasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Amebiasis Total Addressable Market (TAM)

6. Amebiasis Market Segmentation

  • 6.1. Global Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metronidazole
  • Paromomycin
  • Tinidazole
  • 6.2. Global Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous
  • 6.3. Global Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital
  • Pharmacy
  • 6.4. Global Amebiasis Market, Sub-Segmentation Of Metronidazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Metronidazole
  • Intravenous Metronidazole
  • Combination Therapy with Metronidazole
  • 6.5. Global Amebiasis Market, Sub-Segmentation Of Paromomycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Paromomycin
  • Paromomycin in Combination with Other Drugs
  • 6.6. Global Amebiasis Market, Sub-Segmentation Of Tinidazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Tinidazole
  • Tinidazole for Severe Infections

7. Amebiasis Market Regional And Country Analysis

  • 7.1. Global Amebiasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Amebiasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Amebiasis Market

  • 8.1. Asia-Pacific Amebiasis Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Amebiasis Market

  • 9.1. China Amebiasis Market Overview
  • 9.2. China Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Amebiasis Market

  • 10.1. India Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Amebiasis Market

  • 11.1. Japan Amebiasis Market Overview
  • 11.2. Japan Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Amebiasis Market

  • 12.1. Australia Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Amebiasis Market

  • 13.1. Indonesia Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Amebiasis Market

  • 14.1. South Korea Amebiasis Market Overview
  • 14.2. South Korea Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Amebiasis Market

  • 15.1. Western Europe Amebiasis Market Overview
  • 15.2. Western Europe Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Amebiasis Market

  • 16.1. UK Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Amebiasis Market

  • 17.1. Germany Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Amebiasis Market

  • 18.1. France Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Amebiasis Market

  • 19.1. Italy Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Amebiasis Market

  • 20.1. Spain Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Amebiasis Market

  • 21.1. Eastern Europe Amebiasis Market Overview
  • 21.2. Eastern Europe Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Amebiasis Market

  • 22.1. Russia Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Amebiasis Market

  • 23.1. North America Amebiasis Market Overview
  • 23.2. North America Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Amebiasis Market

  • 24.1. USA Amebiasis Market Overview
  • 24.2. USA Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Amebiasis Market

  • 25.1. Canada Amebiasis Market Overview
  • 25.2. Canada Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Amebiasis Market

  • 26.1. South America Amebiasis Market Overview
  • 26.2. South America Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Amebiasis Market

  • 27.1. Brazil Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Amebiasis Market

  • 28.1. Middle East Amebiasis Market Overview
  • 28.2. Middle East Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Amebiasis Market

  • 29.1. Africa Amebiasis Market Overview
  • 29.2. Africa Amebiasis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Amebiasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Amebiasis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Amebiasis Market Competitive Landscape And Company Profiles

  • 30.1. Amebiasis Market Competitive Landscape
  • 30.2. Amebiasis Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Amebiasis Market Other Major And Innovative Companies

  • 31.1. Thermo Fisher Scientific Inc.
  • 31.2. Novartis AG
  • 31.3. F. Hoffmann-La Roche Ltd
  • 31.4. Eli Lilly and Company
  • 31.5. Takeda Pharmaceutical Company Limited
  • 31.6. Boehringer Ingelheim International GmbH
  • 31.7. Siemens Healthineers AG
  • 31.8. Becton Dickinson and Company
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Cipla Limited
  • 31.11. Hikma Pharmaceuticals PLC
  • 31.12. Lupin Limited
  • 31.13. Cepheid Inc.
  • 31.14. Mission Pharmacal Company
  • 31.15. Profounda Inc.

32. Global Amebiasis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Amebiasis Market

34. Recent Developments In The Amebiasis Market

35. Amebiasis Market High Potential Countries, Segments and Strategies

  • 35.1 Amebiasis Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Amebiasis Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Amebiasis Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제